The company's worst days might be behind it.

Americans without health insurance could be paying more than 10 times as much for the weight-loss drugs.

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

The launch comes amid the company’s legal battle with Indian drugmakers, including Dr Reddy’s Laboratories and Sun Pharma, ...

Earlier, the court had declined Novo’s plea for an interim injunction against Dr Reddy’s Labs and permitted the company to ...

By Soren Jeppesen COPENHAGEN, Dec 4 (Reuters) - Denmark on Thursday sharply raised its economic growth forecast for 2025, due ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Ascendis Pharma's Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, nearly quadrupling year-over-year. Read why ...

The issues are piling on for the healthcare leader, but this one is nowhere near insurmountable.

Novo Nordisk has intensified its legal push in India by filing a plea against Sun Pharma, seeking to delay competition in the ...

Novo Nordisk Moves to higher Bench to Block Dr. Reddy’s Semaglutide Exports ...

By Rishika Sadam HYDERABAD, India, Dec 3 (Reuters) - Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug ...